The Supraphysiological Problem
Where Replacement Ends and Anabolic Steroid Use Begins
Evidence grade 4 of 5, Strong. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- Testosterone is a Schedule III controlled substance; performance-enhancement prescribing is off-label/inappropriate
- WADA
- Prohibited (S1 Anabolic Agent)
Reference only. Not medical advice.
This is something to take to a clinician. The Atlas can tell you what is known about the supraphysiological problem in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
Supraphysiological testosterone means serum levels above the natural peak, generally above 1000-1500 ng/dL. At these levels the intervention is no longer replacement; it is effectively anabolic steroid use, with a different and less-studied risk profile. This entry maps the dose spectrum, explains how telehealth prescribing and the desire to 'feel better' push men upward, and details the health risks the marketplace tends to conflate away.
Same molecule, different medicine, the boundary is drawn by dose and intent, not by the drug.
What people take it for
What it is taken for. Approval, where it exists, covers only some of these.
- Hypogonadal
- Below 300 ng/dL, clinically low, treatment-indicated
- Low-normal
- 300-500 ng/dL, frequently treated by telehealth; legitimate controversy over whether this range warrants treatment
- Normal
- 500-900 ng/dL, no deficiency treatment indicated
- High-normal
- 900-1000 ng/dL, upper physiological range
- Supraphysiological
- Above 1000-1500 ng/dL, effectively anabolic steroid territory
How it works
Anabolic and androgenic effects scale with androgen-receptor occupancy, which rises with serum concentration. At physiological replacement levels the effects are restorative. Above the natural ceiling, the same receptor signaling drives muscle accretion and performance benefits, which men accurately perceive as 'feeling better', alongside escalating risks. Excess testosterone aromatizes to estradiol (gynecomastia) and reduces to DHT (acne, hair loss); erythropoiesis is overdriven (polycythemia); and the HPG axis is fully suppressed (atrophy, azoospermia).
Safety in detail
This intervention involves significant physiological effects and requires evaluation and monitoring by a qualified physician. Self-administration without medical oversight carries documented health risks. Prescribing testosterone for performance enhancement or to men without hypogonadism is off-label and medically inappropriate. Changes to hormones, sexual function, or sexual health warrant evaluation by a qualified healthcare provider.
- Polycythemia (raised hematocrit, increased viscosity and clotting/stroke risk), the primary physiological risk
- Testicular atrophy and azoospermia from HPG-axis suppression; potentially permanent hypogonadism requiring lifelong TRT
- Cardiovascular: elevated hematocrit, adverse LDL/HDL shifts, possible direct myocardial effects and left ventricular hypertrophy at very high doses
- DHT-mediated acne, oily skin, and male-pattern hair loss
- Gynecomastia from aromatization of excess testosterone to estradiol
- Exacerbation of sleep apnea
- Mood effects: aggression and mood instability documented at supraphysiological levels (generally not at replacement doses)
- Liver: not a major concern with injectable/transdermal testosterone; relevant for oral 17-alpha-alkylated androgens used recreationally, not in clinical TRT
Replacement is not the same as a cycle
The TRT-versus-anabolic boundary is not drawn by substance: testosterone cypionate is testosterone cypionate. It is drawn by dose and intent. Clinical TRT (50-150 mg/week) maintains physiological levels in a deficient man; bodybuilding doses (300-1000+ mg/week, often stacked with other anabolics) produce supraphysiological levels by design. The telehealth pathway can become an entry point into this escalation when monitoring is loose and the patient chases the 'better' feeling of higher levels.
What it does to fertility
Supraphysiological dosing maximally suppresses LH and FSH, reliably causing testicular atrophy and azoospermia. Recovery of spermatogenesis after long-term high-dose use can be slow, incomplete, or absent; some men are left with permanent hypogonadism. This is among the most underdisclosed consequences of crossing from replacement into anabolic dosing.
What people get wrong
Often saidIf TRT is safe (TRAVERSE), then more must be fine
ActuallyTRAVERSE tested physiological replacement in confirmed hypogonadal men. It says nothing reassuring about supraphysiological dosing, whose cardiovascular and other risks are understudied and, in case series, concerning.
Often saidA standard telehealth dose is always replacement
ActuallyIf a man is not actually deficient, 200 mg/week can drive his peak past 1500 ng/dL. That is not replacement, it is anabolic steroid use, regardless of the prescription label.
Who profits, and who pushes back
Endocrine Society Guideline Panel
Therapy should target the mid-normal range; pushing levels into the high-normal or supraphysiologic zone to chase symptom relief is not supported by evidence and raises avoidable risk.
Shalender Bhasin
Anabolic and adverse effects both scale with dose; supraphysiologic testosterone reliably increases muscle but the long-term safety of such doses has not been established in controlled trials.
Harrison Pope and colleagues
Many men using supraphysiologic androgens experience underrecognized cardiovascular, endocrine, and psychiatric harms, and the line between 'optimization' and anabolic steroid use is frequently blurred.
How we got here
Supraphysiologic androgen use traces to the late 1930s synthesis of testosterone and its early use for vigor; by the 1950s-1960s synthetic anabolic derivatives spread through competitive weightlifting and Olympic sport. Use expanded into bodybuilding and recreational strength culture through the 1970s-1980s, prompting the 1990 U.S. Anabolic Steroids Control Act that placed testosterone and related compounds in Schedule III. Bhasin's landmark 1996 trial then demonstrated that supraphysiologic testosterone increases muscle mass and strength even without exercise, scientifically confirming what athletes had long exploited. More recently, the rise of 'low T' marketing and telehealth prescribing has created a gray zone in which above-range dosing is reframed as wellness optimization.
- 1935Testosterone first isolated and synthesized.
- 1950s-1960sSynthetic anabolic steroids proliferate in competitive sport.
- 1976IOC bans anabolic steroids; testing introduced.
- 1990U.S. Anabolic Steroids Control Act schedules testosterone (Schedule III).
- 1996Bhasin NEJM trial confirms supraphysiologic dosing builds muscle without exercise.
- 2010s-2020s'Low T' marketing and telehealth blur replacement and supraphysiologic use.
Set against the alternatives
The defining contrast is dose and intent: replacement aims to restore a deficient man to mid-normal physiology and is supported by trial-grade safety data such as TRAVERSE, whereas supraphysiologic dosing deliberately exceeds the natural ceiling to maximize anabolic effect and falls into the evidence gap occupied by anabolic steroid use. Compared with replacement, supraphysiologic use offers larger gains in muscle and performance that users accurately perceive as 'feeling better,' but at the cost of near-certain polycythemia, fuller HPG suppression with infertility, and cardiovascular risks that have never been tested in adequately powered randomized trials. The marketplace, especially some telehealth channels, tends to conflate the two by framing high-normal or above-range targets as routine optimization.
| Parameter | Physiologic replacement | Supraphysiologic/anabolic | Concern |
|---|---|---|---|
| Typical dose | 50-150 mg/week | 300-1000+ mg/week equivalents | Receptor saturation, escalating risk |
| Target serum level | Mid-normal (~400-700 ng/dL) | Above ~1000-1500 ng/dL | Beyond natural ceiling |
| Muscle/strength effect | Restorative | Marked anabolic gains | Drives the 'feel better' pull |
| Hematocrit | Mild rise, monitored | Polycythemia common | Thrombosis risk |
| HPG axis | Suppressed, often reversible | Fully suppressed | Atrophy, azoospermia |
| Cardiovascular | Studied (TRAVERSE) | Largely unstudied at these doses | Dyslipidemia, LVH, events |
What we do not know
- What is the cardiovascular risk of sustained supraphysiologic testosterone, which no large RCT has directly tested?
- Is there a serum threshold above which risk accelerates disproportionately to benefit?
- How reversible is HPG-axis suppression and fertility loss after prolonged supraphysiologic exposure?
- Do the cognitive and mood effects men report at high-normal levels reflect true benefit or expectation?
- Can monitoring protocols meaningfully mitigate harm in men who choose supraphysiologic dosing?
What could change
Telehealth guardrailsRegulatory and professional scrutiny of online prescribing that targets above-range levels.Long-term safety registriesEfforts to capture outcomes in men using above-replacement doses outside formal trials.SARMs and designer androgensMarketed as 'safer' anabolic options despite lacking approval and long-term safety data.Polycythemia managementRefined monitoring and therapeutic-phlebotomy strategies for hematocrit driven by high doses.
At a glance
- Healthy young-male peak
- ~600-900 ng/dL
- High-normal
- 900-1000 ng/dL
- Supraphysiological
- Above ~1000-1500 ng/dL
- TRT dose
- 50-150 mg/week
- Anabolic dose
- 300-1000+ mg/week equivalents
- Legal status
- Schedule III controlled substance
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about The Supraphysiological Problem. A short entry is not a safe entry.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- Children and teenagers. We have not checked what is known about younger people.
- What can go wrong. We have not written the risk line for this one. Read the safety section below rather than treating its absence as reassurance.
Sources
The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.
The studies that matter
Bhasin et al. dose-response work and anabolic-steroid case series1990s-2010s
Supraphysiological testosterone produces dose-dependent gains in muscle and strength alongside documented harms; competitive-bodybuilder case series link very high doses to left ventricular hypertrophy, adverse lipid shifts, and sudden cardiac death